Cargando…

Long-term effects of ruxolitinib versus best available therapy on bone marrow fibrosis in patients with myelofibrosis

BACKGROUND: Myelofibrosis (MF) is a life-shortening complication of myeloproliferative neoplasms associated with ineffective hematopoiesis, splenomegaly, and progressive bone marrow (BM) fibrosis. The oral Janus kinase (JAK) 1/JAK2 inhibitor ruxolitinib has been shown to improve splenomegaly, sympto...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kvasnicka, Hans Michael, Thiele, Jürgen, Bueso-Ramos, Carlos E., Sun, William, Cortes, Jorge, Kantarjian, Hagop M., Verstovsek, Srdan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2018
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5856218/ https://www.ncbi.nlm.nih.gov/pubmed/29544547 http://dx.doi.org/10.1186/s13045-018-0585-5

Ejemplares similares

Ruxolitinib for the treatment of myelofibrosis: its clinical potential
por: Ostojic, Alen, et al.
Publicado: (2012)

Overcoming treatment challenges in myelofibrosis and polycythemia vera: the role of ruxolitinib
por: Bryan, Jeffrey C., et al.
Publicado: (2016)

Management of cytopenias in patients with myelofibrosis treated with ruxolitinib and effect of dose modifications on efficacy outcomes
por: Verstovsek, Srdan, et al.
Publicado: (2013)

Evaluation of Ruxolitinib versus Best Available Therapy in Treating Primary Myelofibrosis
por: Hasan, Kawa M., et al.
Publicado: (2022)

Ten years of treatment with ruxolitinib for myelofibrosis: a review of safety
por: Verstovsek, Srdan, et al.
Publicado: (2023)

Primary myelofibrosis associated glomerulopathy: significant improvement after therapy with ruxolitinib
por: Rajasekaran, Arun, et al.
Publicado: (2015)

Cost-effectiveness of Ruxolitinib vs Best Available Therapy in the Treatment of Myelofibrosis in Spain
por: Gómez-Casares, María Teresa, et al.
Publicado: (2017)

Interim analysis of safety and efficacy of ruxolitinib in patients with myelofibrosis and low platelet counts
por: Talpaz, Moshe, et al.
Publicado: (2013)

Efficacy of ruxolitinib on hepatomegaly in patients with myelofibrosis
por: Verstovsek, S, et al.
Publicado: (2016)

Real-world survival of US patients with intermediate- to high-risk myelofibrosis: impact of ruxolitinib approval
por: Verstovsek, Srdan, et al.
Publicado: (2021)

Primary myelofibrosis marrow-derived CD14(+)/CD34(-) monocytes induce myelofibrosis-like phenotype in immunodeficient mice and give rise to megakaryocytes
por: Manshouri, Taghi, et al.
Publicado: (2019)

Replacement of hematopoietic system by allogeneic stem cell transplantation in myelofibrosis patients induces rapid regression of bone marrow fibrosis
por: Kröger, Nicolaus, et al.
Publicado: (2012)

Ruxolitinib for essential thrombocythemia?
por: Bose, Prithviraj, et al.
Publicado: (2017)

Ruxolitinib Re-Treatment in Patients with Myelofibrosis: Real-World Evidence on Patient Characteristics and Outcomes
por: Gerds, Aaron T., et al.
Publicado: (2022)

PB2232: A RANDOMIZED, CONTROLLED CLINICAL TRIAL (PHASE 2B) OF NS-018 VERSUS BEST AVAILABLE THERAPY IN SUBJECTS WITH PRIMARY OR SECONDARY MYELOFIBROSIS WITH SEVERE THROMBOCYTOPENIA
por: Palacio, Melisa, et al.
Publicado: (2023)

Ruxolitinib for myelofibrosis
por: GU, LIAN, et al.
Publicado: (2013)

The use of erythropoiesis-stimulating agents with ruxolitinib in patients with myelofibrosis in COMFORT-II: an open-label, phase 3 study assessing efficacy and safety of ruxolitinib versus best available therapy in the treatment of myelofibrosis
por: McMullin, Mary Frances, et al.
Publicado: (2015)

Matching-adjusted indirect comparison of the pelabresib-ruxolitinib combination vs JAKi monotherapy in myelofibrosis
por: Gupta, Vikas, et al.
Publicado: (2023)

Sustained‐release ruxolitinib: Findings from a phase 1 study in healthy subjects and a phase 2 study in patients with myelofibrosis
por: Verstovsek, Srdan, et al.
Publicado: (2018)

Fedratinib in patients with myelofibrosis previously treated with ruxolitinib: An updated analysis of the JAKARTA2 study using stringent criteria for ruxolitinib failure
por: Harrison, Claire N., et al.
Publicado: (2020)

Ruxolitinib: Long-Term Management of Patients with Myelofibrosis and Future Directions in the Treatment of Myeloproliferative Neoplasms
por: Yacoub, A., et al.
Publicado: (2014)

Optimizing management of ruxolitinib in patients with myelofibrosis: the need for individualized dosing
por: Mesa, Ruben A, et al.
Publicado: (2013)

Long-term survival in patients treated with ruxolitinib for myelofibrosis: COMFORT-I and -II pooled analyses
por: Verstovsek, Srdan, et al.
Publicado: (2017)

How I manage anemia related to myelofibrosis and its treatment regimens
por: Verstovsek, Srdan
Publicado: (2023)

Role of neoplastic monocyte-derived fibrocytes in primary myelofibrosis
por: Verstovsek, Srdan, et al.
Publicado: (2016)

JAK Inhibition for the Treatment of Myelofibrosis: Limitations and Future Perspectives
por: Bose, Prithviraj, et al.
Publicado: (2020)

Ruxolitinib in Myelofibrosis and Polycythemia Vera
por: Wolfe, Leah
Publicado: (2016)

Ruxolitinib in myelofibrosis: to be or not to be an immune disruptor
por: Manduzio, Palma
Publicado: (2017)

A phase Ib study to assess the efficacy and safety of vismodegib in combination with ruxolitinib in patients with intermediate- or high-risk myelofibrosis
por: Couban, Stephen, et al.
Publicado: (2018)

Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis
por: Harrison, C N, et al.
Publicado: (2016)

Momelotinib: an emerging treatment for myelofibrosis patients with anemia
por: Chifotides, Helen T., et al.
Publicado: (2022)

MANIFEST: Pelabresib in Combination With Ruxolitinib for Janus Kinase Inhibitor Treatment-Naïve Myelofibrosis
por: Mascarenhas, John, et al.
Publicado: (2023)

Histomorphological responses after therapy with pegylated interferon α-2a in patients with essential thrombocythemia (ET) and polycythemia vera (PV)
por: Masarova, Lucia, et al.
Publicado: (2017)

Effect of treatment with a JAK2-selective inhibitor, fedratinib, on bone marrow fibrosis in patients with myelofibrosis
por: Jamieson, Catriona, et al.
Publicado: (2015)

Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial
por: Verstovsek, Srdan, et al.
Publicado: (2017)

Ruxolitinib: a targeted treatment option for patients with polycythemia vera
por: Vaddi, Kris, et al.
Publicado: (2016)

Novel Concepts of Treatment for Patients with Myelofibrosis and Related Neoplasms
por: Bose, Prithviraj, et al.
Publicado: (2020)

Erratum: Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis
por: Harrison, C N, et al.
Publicado: (2017)

Ruxolitinib therapy and telomere length in myelofibrosis
por: Caocci, G, et al.
Publicado: (2016)

Management of myelofibrosis after ruxolitinib failure
por: Harrison, Claire N, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_n7uqkrd1rhluc0h8p5ag3r8co2